Alpibectir (GSK3729098)
Phase 2Small molecule
Alpibectir (GSK3729098) is one of 12 small molecule programs targeting NAC. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in NAC
#DrugCompanyPhaseTrials
1Avelox
BayerPhase 2
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Myambutol
VVA Greater Los Angeles Healthcare System
Phase 2
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 2
TB Alliance
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Rifampicin
Boehringer IngelheimPhase 2
Ganfeborole
UUniversity College, London
Phase 2
Trecator
WWyeth-Lederle Vaccines
Phase 2
BTZ-043
GSKPhase 2
N-Acetyl Cyteien
SStanford University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
NAC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alpibectir (GSK3729098). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMichael Hoelscher